You are here
Hong Kong is a Special Administrative Region of the People’s Republic of China. It has one of the highest per-capita incomes in the world, yet also one of the highest income inequalities amongst developed nations.
- 93% Ethnic Chinese population
- Extremely high population density
- One of the longest life expectancies in the world
- 90% medical services provided by public settings
- English and Chinese are joint official languages
- ¾ of HK universities are research based and graduates are both highly skilled and multilingual
- Strong history of medical research innovation and excellence
- High regulatory and ethical standards.
Hong Kong residents have access to an excellent public health system, which has seen their life expectancy increase over the last 40 years to be among the highest in the world (Female 86.4, Male 80.7). Because of this, there is an increased prevalence of diseases associated with aging.
Poor air quality has also led to an increase in respiratory illness.
High prevalence diseases include:
- Heart Disease
Clinical Trial Landscape
Clinical trials are regulated by the Hong Kong Department of Health and respective research Ethics Committees/Institutional review boards (IECs/IRBs).
The average timeline for regulatory and IEC/IRB approval is ~3-4 months.
7.1 million people
100% reside in urban centers
93.5% literacy rate
- Novotech opened its first Hong Kong CRO office in 2013
Why choose Hong Kong for clinical research?
There are many compelling reasons to consider contract research organizations in Hong Kong for your clinical research:
- Hong Kong is the third most active industry sponsored clinical trial city in Asia after Seoul and Taipei
- Global and regional KOLs in various specialties, especially cardiology, gastroenterology, hepatology, oncology and endocrinology
- Hong Kong is officially recognized by China Food and Drug Administration (CFDA) for conducting clinical trials for drug registration purpose in mainland China in certain therapeutic areas
- Government supported Phase I centers (USD 5.4 million investment)
- Regulatory and Ethics submission in English, and in parallel process
- Device and non-interventional studies require only Ethics approval
- Mixture of fully reimbursed and self-financed drugs systems
- Well established legal system with strong intellectual property protection
- Research dedicated investigators, staff and high quality facilities.